ArticleBreast cancer (Tokyo, Japan)2019

Patients' preferences for postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer treatments in Japan.

Yukie Omori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.